• Shao-Huan Lan, Chi-Kuei Hsu, Shen-Peng Chang, Li-Chin Lu, and Chih-Cheng Lai.
• School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian, China.
• Ann. Med. 2023 Dec 1; 55 (1): 22088722208872.

ObjectiveThis study evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19.MethodsThe PubMed, Web of Science, Ovid Medline, Embase and Cochrane Library databases were searched for relevant articles from their inception to 25 September 2022. Only randomized clinical trials (RCTs) that assessed the clinical efficacy and safety of IL-1 blockade in the treatment of patients with COVID-19 were included.ResultsThis meta-analysis included seven RCTs. No significant difference in the all-cause mortality rate of patients with COVID-19 was observed between the IL-1 blockade and control groups (7.7 vs. 10.5%, odds ratio [OR] = 0.83, 95% confidence interval [CI] 0.57-1.22; I2 = 18%). However, the study group was at significantly lower risk of requiring mechanical ventilation (MV) compared with the control group (OR = 0.53, 95% CI 0.32-0.86; I2 = 24%). Finally, the risk of adverse events was similar between the two groups.ConclusionsIL-1 blockade does not provide increased survival benefits in hospitalized patients with COVID-19, but it may reduce the need for MV. Furthermore, it is a safe agent for use in the treatment of COVID-19.>.

10 keywords...

hide…